FDC Ltd. (IN:FDC)
:FDC
Top Page
FDC Ltd.
(FDC)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹360.00
▼(-12.22% Downside)
Action:ReiteratedDate:11/11/25
FDC Ltd.'s overall stock score is primarily influenced by its solid financial performance, which is offset by bearish technical indicators and a high valuation. The company's strong balance sheet and operational efficiency are positive factors, but the stock's current technical weakness and relatively high P/E ratio present challenges.
Positive Factors
Balance sheet strength
Conservative leverage and a high equity ratio provide durable financial flexibility: they reduce refinancing risk, lower interest burden, and allow the company to fund R&D, regulatory processes or opportunistic M&A. This balance-sheet strength supports resilience across industry cycles.
Negative Factors
Earnings decline
A ~21% drop in EPS signals notable pressure on per-share profitability that can persist if underlying causes (pricing, higher costs, one-offs) are structural. Lower EPS reduces retained earnings accumulation and may constrain reinvestment, dividend growth, or share repurchase capacity over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Conservative leverage and a high equity ratio provide durable financial flexibility: they reduce refinancing risk, lower interest burden, and allow the company to fund R&D, regulatory processes or opportunistic M&A. This balance-sheet strength supports resilience across industry cycles.
Read all positive factors
FDC Ltd. (FDC) vs. iShares MSCI India ETF (INDA)
Market Cap
₹56.41B
Dividend Yield1.22%
Average Volume (3M)16.03K
Price to Earnings (P/E)60.8
Beta (1Y)0.81
Revenue Growth0.25%
EPS Growth-28.79%
CountryIN
Employees6,659
SectorServices
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.74
Shares Outstanding162,810,090
10 Day Avg. Volume4,978
30 Day Avg. Volume16,030
Financial Highlights & Ratios
PEG Ratio-2.10
Price to Book (P/B)2.86
Price to Sales (P/S)3.10
P/FCF Ratio24.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FDC Ltd. Business Overview & Revenue Model
Company Description
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/mineral...
How the Company Makes Money
null...
FDC Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.77B | 21.08B | 19.35B | 17.84B | 15.26B | 13.27B |
| Gross Profit | 12.64B | 8.36B | 6.51B | 11.28B | 9.78B | 9.00B |
| EBITDA | 3.66B | 4.15B | 4.40B | 3.01B | 3.30B | 4.29B |
| Net Income | 2.25B | 2.67B | 3.05B | 1.94B | 2.16B | 3.01B |
Balance Sheet | ||||||
| Total Assets | 28.86B | 27.14B | 24.68B | 23.43B | 22.70B | 19.56B |
| Cash, Cash Equivalents and Short-Term Investments | 4.52B | 5.37B | 4.75B | 4.84B | 5.39B | 5.57B |
| Total Debt | 207.12M | 211.68M | 205.19M | 283.20M | 322.04M | 146.56M |
| Total Liabilities | 4.54B | 4.33B | 3.71B | 3.62B | 3.14B | 2.22B |
| Stockholders Equity | 24.31B | 22.81B | 20.97B | 19.82B | 19.57B | 17.34B |
Cash Flow | ||||||
| Free Cash Flow | -833.81M | 2.67B | 1.27B | 418.21M | 291.08M | 1.45B |
| Operating Cash Flow | -19.40M | 3.64B | 2.21B | 1.55B | 1.62B | 2.07B |
| Investing Cash Flow | -68.14M | -2.47B | -170.83M | 111.35M | -1.45B | -771.54M |
| Financing Cash Flow | -70.98M | -913.47M | -2.02B | -1.80B | -98.37M | -1.29B |
FDC Ltd. Technical Analysis
Negative
410.10
Price Trends
360.82
Negative
383.18
Negative
423.19
Negative
Market Momentum
-9.88
Negative
44.73
Neutral
77.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FDC, the sentiment is Negative. The current price of 410.1 is above the 20-day moving average (MA) of 343.08, above the 50-day MA of 360.82, and below the 200-day MA of 423.19, indicating a bearish trend. The MACD of -9.88 indicates Negative momentum. The RSI at 44.73 is Neutral, neither overbought nor oversold. The STOCH value of 77.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FDC.
FDC Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹74.18B | 20.41 | ― | 4.98% | 7.10% | 29.89% | |
70 Outperform | ₹77.32B | 18.01 | ― | 0.94% | 9.97% | 16.28% | |
60 Neutral | ₹53.90B | 55.57 | ― | 0.40% | 11.56% | -2.78% | |
59 Neutral | ₹48.14B | 41.31 | ― | 0.32% | 11.02% | -9.59% | |
58 Neutral | ₹56.41B | 60.85 | ― | 1.22% | 0.25% | -28.79% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
53 Neutral | ₹47.15B | 21.04 | ― | 0.23% | -30.54% | -35.13% |
* Services Sector Average
IN:FDC
FDC Ltd.
346.50
-54.44
-13.58%
IN:GPPL
Gujarat Pipavav Port Limited
153.45
26.17
20.56%
IN:IONEXCHANG
Ion Exchange (India) Ltd.
367.50
-94.11
-20.39%
IN:PNCINFRA
PNC Infratech Ltd
183.80
-72.95
-28.41%
IN:TCI
Transport Corporation of India Limited
1,007.50
-49.11
-4.65%
IN:THOMASCOOK
Thomas Cook (India) Limited
102.34
-21.48
-17.35%
FDC Ltd. Corporate Events
FDC Gets USFDA ANDA Nod for Fluconazole Tablets
Jan 9, 2026
FDC Ltd. has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application covering Fluconazole Tablets USP in strengths of 50 mg, 100 mg, 150 mg and 200 mg. The clearance enables FDC to market a generic ver...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.